Leading the Way in Life Science Technologies

GEN Exclusives

More »

May. 15, Vol. 25, No. 10

    • Feature Articles

      • Cutting Through the Biomarker Hype
      • Elizabeth Lipp
      • Scientists trying to improve the productivity and efficiency of their drug discovery efforts still face issues of escalating R&D costs and the lengthy time it takes to conduct clinical trials. As a result, biotech and pharma companies are lookin ... more »
      • Growth of Virginia's Life Science Clusters
      • Strategically located near Federal institutions (like the National Institutes of Health) and regulatory agencies (like the Food and Drug Administration), Virginia is an ideal place for life science companies. According to the Virginia Biotechnology ... more »
      • Moving Toward System-Wide Software Suites
      • Gail Dutton
      • Electronic clinical trials are moving from standalone, point solutions toward software suites, similar to the way office applications migrated in the 1980s. Eventually, investigators will have a seamless, system-wide software suite on a single platf ... more »
      • Preparation of Clinical Trials Materials
      • Contract preparation of clinical trial materials has been a growing business since the mid 1980s in Europe and the 1990s in the U.S., explains Gary Sutterlin, director of clinical trial project management at Cardinal Health (Philadelphia). Prior to ... more »
      • Signal Pathways Making Inroads in Discovery
      • Signal pathways control a vast range of cellular events and keep cells operating cohesively. Extracellular changes are communicated inside cells via cell-surface receptors, like tyrosine kinase, G-protein coupled receptors, and ion-channel receptors ... more »
    • FDA News and Analysis

      • Regulation of Combination Products by the FDA
      • Combination products, i.e., those containing any combination of a drug, device, or biological, constitute a growing category of innovative medical products. Examples include a drug with an implantable delivery device, drug-eluting cardiovascular ste ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »